Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Disease sites
  • Prostate
  • Stage distribution

Stage distribution

  • Charts and Tables

    Charts and Tables

    Figure 3.9

    Distribution of cases by stage at diagnosis for prostate cancer – 2013 diagnosis year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    Includes BC, AB, SK, MB, NB, NS, PE, NL. ON is not included because ON excludes stage 0 from stage distribution reporting.
    Data for Stage Not Available suppressed owing to small numbers.
    Data source: Provincial cancer agencies and programs.

    Data Table

    Stage at DiagnosisNumber of CasesPercent (%)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    Stage I1,55219.618.720.4
    Stage IIA1,79422.621.723.5
    Stage IIB2,20727.826.928.8
    Stage III96212.111.412.9
    Stage IV96012.111.412.8
    Stage Unknown4525.75.26.2

    + Expand Table

    Includes BC, AB, SK, MB, NB, NS, PE, NL. ON is not included because ON excludes stage 0 from stage distribution reporting.
    Data for Stage Not Available suppressed owing to small numbers.
    Data source: Provincial cancer agencies and programs.

    Figure 3.10

    Distribution of cases by stage at diagnosis for ovarian cancer – 2013 diagnosis year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    Includes BC, AB, SK, MB, NB, NS, PE, NL. ON is not included because ON excludes stage 0 from stage distribution reporting.
    Data for Stage IB, Stage I Not Otherwise Specified, Stage II, and Stage II Not Otherwise Specified suppressed owing to small numbers.
    Data source: Provincial cancer agencies and programs.

    Data Table

    Stage at DiagnosisNumber of CasesPercent (%)Lower bound of 95% confidence intervalUpper bound of 95% confidence interval
    Stage IA6212.19.314.9
    Stage IC6312.39.515.2
    Stage IIA102.00.83.2
    Stage IIB132.51.23.9
    Stage IIC142.71.34.1
    Stage IIIA244.72.96.5
    Stage IIIB142.71.34.1
    Stage IIIC15931.12735.1
    Stage III Not Otherwise Specified407.85.510.1
    Stage IV9518.615.221.9
    Stage Unknown193.72.15.3

    + Expand Table

    Includes BC, AB, SK, MB, NB, NS, PE, NL. ON is not included because ON excludes stage 0 from stage distribution reporting.
    Data for Stage IB, Stage I Not Otherwise Specified, Stage II, and Stage II Not Otherwise Specified suppressed owing to small numbers.
    Data source: Provincial cancer agencies and programs.

  • Data specifications

    Data specifications

    Definition: The percentage breakdown of incident cases by stage at diagnosis for breast, lung, colorectal, prostate and ovarian cancer

    Numerator: Number of stageable* incident cases in the provincial cancer registry for each stage at diagnosis (stage 0 – IV including occult, “Unknown”)

    Denominator: Total number of stageable incident cases (stage 0 through to “Not Available”)

    Exclusions:

    • Age (at diagnosis) 0 – 17
    • Non-melanoma skin cancer (M8050-8110 with site code C44.0 to C44.9)
    • Colorectal reporting for appendix C18.1
    • Lymphoma codes M-95 to M-98, all sarcoma codes

    Data source: Provincial cancer agencies

    Measurement timeframe: 2013 diagnosis year

    Stratification variable: Stage at diagnosis, disease site (breast, prostate, colorectal, lung (NSCLC, SCLC), ovarian)

    Provinces submitting data: BC, AB, SK, MB, NB, NS, PE, NL

    Province-specific notes:

    • AB: Hematology, sarcoma and melanoma morphologies were removed from the site-specific cancers. All 2012-2013 invasive primaries are collaboratively staged and once coded there should be no cases with missing/not available stage values. Currently “Not Available” indicates the number of cases that have a missing stage at the time of data pull as the registry status was not complete and staging information is still to come. Certain skin c44 with morphologies other than basal-squamous are also not staged according to Alberta Cancer Registry (ACR) rules. For this indicator, codes 8002, 8073 and 8803 are included as NSCLC.
    • SK: The denominator includes incident cases for which stage is recorded as “Not Applicable” since SK does not differentiate between “Not Applicable” and “Not Available” categories.
    • ON: Data submitted exclude stage 0 cases and thus are not presented in the stage distribution figure. ‘Breast’ only includes female breast cancer cases.
    • NB: From 2008 onwards, only the four most common cancers (breast, colorectal, lung and prostate cancers) are staged.

    Notes:

    1. The group stages for cancer incident cases were classified by AJCC Cancer Staging 7th edition.
    2. By AJCC, cancer incident cases are categorized in terms of stage as:
      1. Stageable: including stage 0, stage I through stage IV, stage unknown
      2. Not Applicable: Not stageable through AJCC
      3. Not Available: Cases for which stage data is not available or invalid
      4. Unknown: Cases for which there is insufficient information to ascertain a definitive stage
    3. Stage 0 includes in-situ and invasive cancer cases. Stage occult for lung cancer cases are included as well.
    4. Breast cancer cases only include females.
  • Related indicators

    Related Indicators

    Breast cancer screening

    Participation rate in breast cancer screening programs (%), by jurisdiction – 2014 screening year
    View this indicator
    Colorectal cancer screening

    Participation rate in colorectal cancer screening programs in a 30-month period (%), by jurisdiction – 2013-14 screening years combined
    View this indicator
    Capture of stage

    Percentage of incident cases for which stage data were available in provincial registries, by province, top 4 cancers and all cancers — 2012 and 2013 diagnosis years
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation